Stryker Corporation

New York Stock Exchange
Back to all articles
Slightly Bullish +25

Here's Why You Should Hold Stryker Stock in Your Portfolio for Now - TradingView

📈 Stryker (SYK) holds a Zacks Rank #3 (Hold) with shares down 13.1% YTD versus the industry's 23.1% decline.

💻 A recent cyberattack disrupted Q1 manufacturing and revenue recognition, causing adjusted gross margin to decline 190 basis points.

🤖 The Mako robotics platform achieved record installations globally with increasing utilization rates and new handheld solutions launching.

🌍 International operations are becoming a major growth engine with strong momentum in Japan, Europe, India, and the Middle East.

💰 Management expects SYK's bottom line to improve 10.6% over the next five years despite current margin pressures.

📉 Q2 2026 revenue consensus is pegged at $6.56 billion, implying an 11.5% year-over-year growth in earnings.

⚠️ Margin expansion faces headwinds from tariffs, rising input costs, freight expenses, and geopolitical developments.

🔬 Expansion into peripheral vascular intervention and AI-enabled hospital solutions adds execution complexity and regulatory uncertainty.

🛡️ Management successfully restored manufacturing systems after the cyberattack but warns of future cybersecurity threats.

📊 The company has a market capitalization of $118.4 billion and operates across Orthopaedics, MedSurg, and Neurotechnology.

Bullish Signals
  • Underlying demand remains healthy with an elevated capital equipment order book providing solid visibility into future revenue.
  • Record Mako installations and increasing utilization rates demonstrate a powerful competitive moat in the robotics ecosystem.
  • International markets offer ample room for expansion, particularly in Japan, Europe, India, and emerging Middle Eastern regions.
  • SYK has beaten earnings estimates in each of the trailing four quarters with an average negative surprise of only 1.82%.
  • The company is launching new products like Mako RPS handheld robotic solution to broaden access for surgeons.
  • Management reaffirmed full-year guidance despite operational disruptions caused by the recent cyberattack.
  • Consensus estimates for 2026 show a positive revision trend with earnings expected to increase 10.6% over five years.
Risk Factors
  • The cyberattack disrupted manufacturing and shipments, reducing Q1 profitability and highlighting dependence on digital infrastructure.
  • First-quarter adjusted gross margin declined 190 basis points and operating margin fell 180 basis points due to lost absorption and tariffs.
  • Expansion into new categories like cardiovascular technologies increases execution risk and capital investment uncertainty.
  • Future cybersecurity threats remain a material risk given the increasingly digital nature of healthcare operations.
  • Tariff uncertainty could limit earnings growth even if revenue recovery proceeds according to plan.
Full Analysis
Stryker Corporation (SYK) is a global medical technology leader with a market cap of $118.4 billion, operating in Orthopaedics, MedSurg, and Neurotechnology. Despite facing an unexpected cyber disruption that impacted first-quarter results, the company maintains strong underlying demand, a robust capital order book, and significant international momentum. Management emphasizes that organic sales growth was constrained by shipment delays rather than weakening customer demand. The article highlights Stryker's strategic advantages in its robotics ecosystem, particularly the Mako platform, which saw record installations and increasing utilization rates globally. The company is expanding this ecosystem with new handheld solutions and advanced hip revision procedures to strengthen its competitive moat. International markets, including Japan, Europe, India, and the Middle East, are emerging as major growth engines with significant room for market share expansion. However, Stryker faces several headwinds including margin pressures from tariffs, inflation, and lost manufacturing absorption following the cyberattack. The company also takes on execution risks by expanding into newer categories like cardiovascular technologies and AI-enabled solutions, which adds operational complexity. Analysts note a positive estimate revision trend for 2026, with earnings expected to improve 10.6% over the next five years. Zacks Investment Research maintains a 'Hold' rating (Rank #3) on SYK, noting its shares have underperformed the industry and S&P 500 year-to-date despite solid fundamentals. The consensus estimate for second-quarter 2026 revenues is pegged at $6.56 billion, implying an 11.5% bottom-line growth. While the cyberattack exposes operational vulnerabilities, management has successfully restored systems and reaffirmed full-year guidance.